Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma

Affiliations

• ¹ Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
• ² University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
• ³ National Cancer Institute, Bethesda, MD, USA.
• ⁴ Chao Family Comprehensive Cancer Center, University of California-Irvine, Irvine, CA, USA.
• ⁵ Willamette Valley Cancer Institute and Research Center, US Oncology Research, Eugene, OR, USA.
• ⁶ Texas Oncology, Austin, TX, USA.
• ⁷ AstraZeneca, South San Francisco, CA, USA.
• ⁸ AstraZeneca, Gaithersburg, MD, USA.
• ⁹ Knight Cancer Institute, Oregon Health and Sciences University, Portland, OR, USA.